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Abstract
Background: Case reports suggest there may be an association between celiac disease (CD) and myasthenia gravis (MG).
Methods: We identified 29,086 individuals with CD in Sweden from 1969 to 2008. We compared these individuals with
144,480 matched controls. Hazard ratios (HRs) for future MG (identified through ICD codes) were estimated using
Cox regression.
Results: During 326,376 person-years of follow-up in CD patients, there were 7 MG cases (21/million person-years)
compared to 22 MG cases in controls during 1,642,273 years of follow-up (14/million person-years) corresponding to a
HR of 1.48 (95% CI = 0.64–3.41). HRs did not differ when stratifying for age, sex or calendar period. HRs were highest in
the first year after follow-up, though insignificant. Individuals with CD were at no increased risk of MG more than
5 years after CD diagnosis (HR = 0.70; 95% CI = 0.16–3.09).
Conclusion: This study found no increased risk of MG in patients with CD.
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Background
Celiac disease (CD) is an immune mediated chronic
disease that affects the proximal small intestine [1]. An
increased susceptibility to other immune mediated dis-
eases such as type 1 diabetes (T1D), rheumatoid arth-
ritis, and Sjogren’s disease has been well described in
association with CD [2]. Myasthenia Gravis (MG) is a
rare immune mediated disease involving the neuromus-
cular junction with a prevalence estimate of 11.71 to 32/
100,000, which also includes cases of mild or pure ocular
MG [3–6]. CD is common with a 1% prevalence esti-
mate [7–9]. Reports of fatigue and muscle weakness may
suggest that MG is also present in CD as described in
several case reports [10–12]. CD has also been found to
precede a documented diagnosis of MG in the popula-
tion based Swedish Patient Register with a 1.7 odds ratio
of developing MG after a diagnosis of CD, [13] This ana-
lysis did however utilize hospital-based CD diagnoses with
the subsequent risk of overestimating the association
between CD and MG. In Sweden, like in the United
States, many patients with CD are never admitted to
the hospital [14].
Serological markers associated with MG have been re-
ported in CD cases [15]. A retrospective analysis of 23
acetylcholine receptor (AChR) antibody patients, re-
vealed one patient with both IgA-endomysial and IgA
tissue transglutaminase antibodies. This single patient
had a subsequent endoscopic evaluation that was con-
sistent with CD [15]. In another series, one out of 70
CD patients and one out of ten control patients with
systemic lupus erythromatosus had elevated muscle
AChR antibody levels [16]. In addition, human leukocyte
antigen (HLA) types B8 and DR3 appear to be associ-
ated with both MG and CD suggesting a shared im-
mune origin [17, 18].
The objective of our study was to examine the rela-
tive risk and absolute risk of developing MG in a na-
tionwide population-based sample of patients with
biopsy-verified CD.
Methods
We used nationwide biopsy data from Sweden’s 28 path-
ology departments to identify CD cases. These data were
* Correspondence: jonasludvigsson@yahoo.com
4Department Medical Epidemiology and Biostatistics, Karolinska Institutet,
171 77 Stockholm, Sweden
5Department of Pediatrics, Örebro University Hospital, Örebro University,
Örebro, Sweden
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thawani et al. BMC Neurology  (2018) 18:28 
https://doi.org/10.1186/s12883-018-1035-2
then linked to the Swedish Patient Register containing
both inpatient and hospital-based outpatient data to as-
certain the risk of MG [19].
Study participants
Between October 2006 and February 2008 we collected
data from small intestinal biopsy reports from all 28
Swedish pathology departments. Biopsies had been con-
ducted between 1969 and 2008 (Table 1). We obtained
data on date of biopsy, topography (duodenum or je-
junum), morphology codes consistent with villous atro-
phy (VA) which was used as our definition for CD) and
personal identity number [20]. For each patient with CD,
the government agency Statistics Sweden identified up
to five reference individuals from the Total Population
Register. Matching criteria were age, sex, calendar year
and county. We then removed individuals with data ir-
regularities, and thereafter had data on 29,096 individ-
uals with CD and 144,520 reference individuals
(identical to the cohort used in our earlier paper on CD
and mortality) [21].
Celiac disease
CD was defined as VA (Marsh stage 3) according to bi-
opsy report [22]. Having a positive CD serologic test re-
sult was not a prerequisite for CD diagnosis although
88% of individuals in a random subset of individuals
with VA and available data on serology had positive CD
serology at the time of biopsy [23]. Additional details on
the data collection has been published elsewhere [23].
On average, three tissue specimens were examined for
each biopsy report.
Myasthenia gravis (MG)
MG was defined according to relevant international clas-
sification of disease (ICD) codes in the Swedish National
Patient Register: ICD7: 744.00; ICD8: 733.00; ICD9:
358A; ICD10: G70.0. The Patient Register started in
1964 and contains diagnoses from ICD-7 through ICD-
10. The Patient Register included inpatient care but
since 2001, hospital-based outpatient care has also been
included. We did not have access to data on acetylcho-
line receptor antibody results, but National Patient
Register-based MG diagnosis has been validated against
the Stockholm MG Cohort. This analysis found that
147/177 diagnoses in the Patient Register could be con-
firmed against the Stockholm MG Cohort and the posi-
tive predictive value of MG is 83% [13].
Individuals with MG before CD diagnosis and corre-
sponding controls based on dates were excluded from all
prospective analyses (n = 8 and n = 22 respectively). We
then excluded another 2 CD patients and 2 controls due
to data irregularities (uncertainties regarding date of
death) and another 18 reference individuals since their
index individual with CD had been excluded and ana-
lyses were performed retaining strata. Hence, there
remained 29,086 individuals with CD and 144,480
matched controls.
Other covariates
Data on the following potential confounding factors
were collected from the government agency Statistics
Sweden: country of birth (Nordic vs. not Nordic), educa-
tional level (≤9 years of primary school, 2 years of high
school, 3–4 years of high school, college/university) and
socioeconomic status according to six categories (ac-
cording to the European Socioeconomic Classification,
ESeC: levels 1, 2, 3 + 6, 7, 8, and 9) [24]. Missing data on
education and socioeconomic status (4 and 31% respect-
ively) were fitted into separate categories for the statis-
tics. We also identified individuals with T1D and
autoimmune thyroid disease defined according to rele-
vant ICD codes.
Statistical analyses
We estimated hazard ratios (HR) for MG using Cox re-
gression. We used an internal stratification system and
each stratum (consisting of one CD patient and up to
five controls) was analyzed separately and a summary
HR was calculated. Through visual inspection of log-
minus-log curves we found that the proportional hazard
assumption was valid. The attributable risk percent (the
proportion of MG in patients with CD that could be ex-
plained by the underlying CD) was estimated by 1–1/HR.
Table 1 Characteristics of participants presented as n (%)
Characteristics Reference individuals Celiac disease
Total 144,480 29,086
Age at study entry (years)
0–19 58,851 (40.7) 11,802 (40.6)
20–39 26,378 (18.3) 5311 (18.3)
40–59 32,237 (22.3) 6471 (22.2)
60- 27,014 (18.7) 5502 (18.9)
Sex
Female 89,523 (62.0) 17,999 (61.9)
Male 54,957 (28.0) 11,087 (38.1)
Calendar Period
-1989 20,371 (14.1) 4104 (14.1)
1990–1999 59,860 (41.4) 12,055 (41.4)
2000- 64,249 (44.5) 12,947 (44.4)
Nordic 136,242 (94.3) 28,129 (96.7)
Type 1 diabetes 596 (0.4) 956 (3.3)
Autoimmune thyroid diseases 2502 (1.7) 1435 (4.9)
Autoimmune thyroid disease, for definitions
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Follow-up started at first biopsy with CD diagnosis
and at the same time in matched controls. Follow-
up ended when one of the following occurred:
death, emigration, first MG diagnosis, or end of study
(December 31, 2009).
In a priori analyses, we examined the time-
dependent risk of MG (time since CD diagnosis: <
1 year, 1–4.99 years; and > 5 years). We also per-
formed analyses stratified by age at diagnosis of
CD (≤19, 20–39, 40–59 and ≥60 years), sex, and
calendar period (− 1989, 1990–99, 2000-). In a sep-
arate analysis we adjusted for country of birth,
education, socioeconomic status, T1D, and auto-
immune thyroid disease.
In order to examine the temporal association between
CD and MG, we also calculated the odds ratios (ORs)
for having a diagnosis of MG prior to the first biopsy for
CD. For this analysis, we used conditional logistic re-
gression comparing each individual with CD with his or
her matched control.
A post-hoc power analysis found that we had an 80%
power at a significance level of 0.05 to detect a HR of
3.1 for MG.
We used SPSS 22 to calculate statistics. P-values < 0.05
were considered statistically significant.
Ethics
This study was approved by the Regional Ethical
Review Board in Stockholm (2006/633–31/4). Because
this was a register-based study, none of the partici-
pants was contacted and all data were anonymized
prior to data analysis [25].
Results
From our prior paper
The median age of CD diagnosis was 30 years (range 0–
95 years). Median year of diagnosis and first biopsy was
1998 (range 1969–2008). Median age at first diagnosis
with MG was 44 years in CD patients and 48 years in
controls. Most study participants were women (Table 1),
and were diagnosed in the 1990s or later.
Risk of future MG in patients with CD
During 326,376 person-years of follow-up in CD pa-
tients, there were seven cases of MG (21 per million
person-years). This compares with 22 MG cases in con-
trols during 1,642,273 person-years of follow-up (14 per
million person-years). This corresponded to a HR of
1.48 (95% CI = 0.64–3.41).
Adjusting for socioeconomic status, education, and
country of birth, had a marginal influence on the HR
Table 2 Risk of myasthenia gravis in patients with celiac disease according to follow-up
Follow-up HR; 95% CI P-value Observed vs. Expected Person-years Incidence ratea Excess riska Attributable
percentage
All 1.48; 0.64–3.41 0.356 7 vs 5 326,376 21 7 32
< 1 year 8.09; 0.70–94.04 0.095 1 vs 0 28,773 35 30 88
1–5 years 2.19 0.69–6.91 0.182 4 vs 2 108,012 37 20 54
> 5 years 0.70; 0.16–3.09 0.640 2 vs 3 189,591 10 −4 −42
Beyond 1 year of follow-up
aMyasthenia gravis cases per 1,000,000 person-years in patients with celiac disease
Table 3 Risk of MG myasthenia gravis in patients with celiac disease. Stratified analyses





< 20 2.60; 0.50–13.60 0.257 2 vs 1 147,218 14 8 62
20–39 1.99; 0.40–9.92 0.402 2 vs 1 60,204 33 16 50
40–59 0.58; 0.07–4.58 0.602 1 vs 2 75,119 13 −10 −74
> =60 1.55; 0.33–7.37 0.581 2 vs 1 43,835 46 16 36
Sex
Female 2.28; 0.82–6.37 0.166 5 vs 2 204,000 24 14 56
Male 0.79; 0.18–3.52 0.760 2 vs 3 122,376 16 −4 −26
Calendar period
-1989 1.33; 0.27–6.48 0.726 1 vs 1 85,893 12 3 25
1990–99 1.16; 0.26–5.29 0.848 2 vs 2 161,814 12 2 14
2000- 2.10; 0.57–7.66 0.264 3 vs 1 78,669 38 20 52
aMyasthenia gravis cases per 1,000,000 person-years in patients with celiac disease
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(HR = 1.68; 95% CI = 0.71–3.94). Excluding the first year
of follow-up, the HR decreased somewhat (HR = 1.29;
5% CI = 0.53–3.14; Table 2). The lower risk estimate be-
yond the first year signaled a higher risk in the immedi-
ate year after CD diagnosis, although the HR in the first
year failed to attain statistical significance (HR = 8.09;
95% CI = 0.70–94.04; p = 0.095).
The difference in risk estimates between men and
women was not statistically significant (Table 3)(p for
interaction = 0.290).There was also no difference in risk
estimates according to age groups (p for interaction =
0.629) or calendar period (p for interaction = 0.863).
Prior MG in patients with CD
Conditional logistic regression found no increased risk
for earlier MG in CD (OR = 1.70; 95% CI = 0.79–3.66).
Discussion
This nationwide population-based study found no asso-
ciation between CD and future MG. The high HR in the
first year of follow-up (8.09) compared to the HR after
more than 5 years (0.70) suggests surveillance bias just
after MG diagnosis.
Recently, Fang et al. also using Swedish data, examined
the autoimmune spectrum in MG and found an OR of
1.7 for earlier CD in MG [13]. The authors however
ascertained CD using the Patient Register. Until the year
2000, the Patient Register only contained inpatient data.
CD rarely requires hospital admission and is primarily
managed and diagnosed in the outpatient setting [14, 26].
Therefore, this earlier study may have identified a larger
proportion of cases with severe CD or severe comorbidi-
ties, thereby pushing the risk estimate upwards.
Previous case reports and retrospective analyses of the
association between CD and MG have examined sero-
logical markers shared between patients with both CD
and MG [12, 15, 16]. Although serological markers could
not be specifically examined in this analysis, validation
studies of CD diagnoses with serological studies was per-
formed in a subset of CD patients undergoing small in-
testinal biopsy, yielding a positive predictive value of
95% [23]. The diagnosis of MG has also been previously
validated in the Patient Register [13, 27]. In addition to
its population-based setting, another strength of this
analysis is that the CD diagnoses were based on small
intestinal biopsy reports [23], which was the gold
standard for diagnosis of CD in Sweden throughout
the study period.
Although our study used nationwide population based
data, this analysis lacked statistical power. MG is rare in
the general population with prevalence estimates ranging
from 15 to 179 cases per million [7, 8]. The diagnosis of
MG was determined by diagnosis codes in this study,
and should be corroborated by electrophysiological and
serum studies. This information was not available in the
Patient Register thus some cases may have been missed.
Some data suggest that, among patients with CD, adher-
ence to a gluten free diet is associated with protection
against other autoimmune diseases [28, 29]. However,
we did not have information on dietary adherence
amongst participants diagnosed with CD to assess if this
had any effect on a later diagnosis of MG.
Conclusions
In conclusion, in this population-based cohort study we
did not demonstrate an increased risk of MG in CD.
This could partly be due to insufficient power since our
power analysis suggested that we could only demon-
strate a 3.1-fold increased risk of MG in CD. However,
our study shows that the absolute risk of MG is low in
CD and we therefore discourage routine testing for
acetylcholine receptor (AChR) antibodies in CD.
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